DGIdb - VELIPARIB Drug Record

VELIPARIB chembl:CHEMBL506871 Antineoplastic

Alternate Names:

ABT-888
VELIPARIB
PARP-1 INHIBITOR ABT-888
ABT 888
2-[(R)-2-METHYLPYRROLIDIN-2-YL]-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
(2R)-2-(7-CARBAMOYL-1H-BENZIMIDAZOL-2-YL)-2-METHYLPYRROLIDINIUM
2-((2R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE
pubchem.compound:11960529
drugbank:07232
chembl:CHEMBL506871
chemidplus:912444-00-9

Drug Info:

Pharmaceutical Developer	Active Biochem
Source Reported Drug Name(s)	Veliparib/ABT-888
Drug Class	PARP Inhibitor
Drug Class	Small molecule inhibitor

(8 More Sources)

Publications:

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Patel et al., 2011, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells., Proc. Natl. Acad. Sci. U.S.A.
Subhash et al., 2016, ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis., Mol. Cancer Ther.
Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science

VELIPARIB PARP2

Interaction Score: 6.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Direct Interaction yes

Notes

PMIDs:
10592235

Sources:
TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial
VELIPARIB PARP1

Interaction Score: 3.72

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Reported Cancer Type Prostate

PMIDs:
10592235

Sources:
TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial
VELIPARIB STAG2

Interaction Score: 2.39

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
24356817 21852505

Sources:
JAX-CKB
VELIPARIB BRCA2

Interaction Score: 2.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
29338080 25589624 26842236 26801247

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC
VELIPARIB PARP3

Interaction Score: 1.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
VELIPARIB ATR

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
VELIPARIB BRCA1

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
25589624 26801247 26842236 25824335 29338080

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC
VELIPARIB ATM

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21300883 27638859

Sources:
ClearityFoundationBiomarkers JAX-CKB
VELIPARIB MET

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB
VELIPARIB PTEN

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Veliparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB

MyCancerGenome: VELIPARIB
- Version: 20-Jun-2017
Alternate Names:

ABT-888 Development Name

VELIPARIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Publications:
CancerCommons: ABT-888
- Version: 25-July-2013
Alternate Names:

11960529 PubChem Drug ID

2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name

ABT-888 Drug Development Name

Drug Info:

Drug Class PARP Inhibitor

Source Reported Drug Name(s) Veliparib/ABT-888

Pharmaceutical Developer Active Biochem

Publications:

JAX-CKB: Veliparib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.

Karginova et al., 2015, Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer., Mol. Cancer Ther.

Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.

CIViC: VELIPARIB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

TTD: ABT-888
- Version: 2020.06.01
Alternate Names:

D0Q7UD TTD Drug ID

Drug Info:

Publications:
TALC: VELIPARIB
- Version: 12-May-2016
Alternate Names:

ABT-888 Drug Synonym

VELIPARIB Drug Generic Name

VELIPARIB Primary Drug Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL506871
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: VELIPARIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: VELIPARIB
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: VELIPARIB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL506871
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
CGI: Veliparib
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	PARP 1, 2 and 3 inhibitor
Direct Interaction	yes
Notes

Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Phase II

combination therapy	Veliparib;Cisplatin
Drug family	PARP inhibitor;Chemotherapy
Alteration	BRCA1:.

Indication/Tumor Type	stomach cancer
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	AZD6482 + Veliparib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

11960529	PubChem Drug ID
2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide	PubChem Drug Name
ABT-888	Drug Development Name

ABT-888	Drug Synonym
VELIPARIB	Drug Generic Name
VELIPARIB	Primary Drug Name

VELIPARIB Drug Record

VELIPARIB chembl:CHEMBL506871 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction PARP 1, 2 and 3 inhibitor Direct Interaction yes Notes

PMIDs: 10592235

Sources: TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PARP 1, 2 and 3 inhibitor Reported Cancer Type Prostate

PMIDs: 10592235

Sources: TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type glioblastoma multiforme Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 24356817 21852505

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Phase II

PMIDs: 29338080 25589624 26842236 26801247

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction PARP 1, 2 and 3 inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Veliparib;Cisplatin Drug family PARP inhibitor;Chemotherapy Alteration BRCA1:.

PMIDs: 25589624 26801247 26842236 25824335 29338080

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type stomach cancer Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 21300883 27638859

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive Approval Status Preclinical

PMIDs: 26779812

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD6482 + Veliparib Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive

PMIDs: None found

Sources: JAX-CKB

MyCancerGenome: VELIPARIB

Alternate Names: ABT-888 Development Name VELIPARIB Generic Name

Drug Info: Drug Class Small molecule inhibitor

Publications:

CancerCommons: ABT-888

Alternate Names: 11960529 PubChem Drug ID 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name ABT-888 Drug Development Name

Drug Info: Drug Class PARP Inhibitor Source Reported Drug Name(s) Veliparib/ABT-888 Pharmaceutical Developer Active Biochem

Publications:

JAX-CKB: Veliparib

Alternate Names:

Drug Info:

CIViC: VELIPARIB

Alternate Names:

Drug Info:

Publications: O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

TTD: ABT-888

Alternate Names: D0Q7UD TTD Drug ID

Drug Info:

Publications:

TALC: VELIPARIB

Alternate Names: ABT-888 Drug Synonym VELIPARIB Drug Generic Name VELIPARIB Primary Drug Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL506871

Alternate Names:

Drug Info:

Publications:

MyCancerGenomeClinicalTrial: VELIPARIB

Alternate Names:

Drug Info:

Publications:

ClearityFoundationBiomarkers: VELIPARIB

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Direct Interaction yes

Notes

PMIDs:
10592235

Sources:
TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

Reported Cancer Type Prostate

PMIDs:
10592235

Sources:
TALC MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions CancerCommons MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
24356817 21852505

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
29338080 25589624 26842236 26801247

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction PARP 1, 2 and 3 inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib;Cisplatin

Drug family PARP inhibitor;Chemotherapy

Alteration BRCA1:.

PMIDs:
25589624 26801247 26842236 25824335 29338080

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type stomach cancer

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
21300883 27638859

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
26779812

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6482 + Veliparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB

Alternate Names:

ABT-888 Development Name

VELIPARIB Generic Name

Drug Info:

Drug Class Small molecule inhibitor

Alternate Names:

11960529 PubChem Drug ID

2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide PubChem Drug Name

ABT-888 Drug Development Name

Drug Info:

Drug Class PARP Inhibitor

Source Reported Drug Name(s) Veliparib/ABT-888

Pharmaceutical Developer Active Biochem

Publications:

O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer

Alternate Names:

D0Q7UD TTD Drug ID

Alternate Names:

ABT-888 Drug Synonym

VELIPARIB Drug Generic Name

VELIPARIB Primary Drug Name